Online inquiry

IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1166MR)

This product GTTS-WQ1166MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1166MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10407MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ12722MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ15963MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ4727MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ11527MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ2097MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ2280MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ119MR IVTScrip™ mRNA-Anti-EGFR, 11F8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 11F8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW